Clinical TrialsAllogene announced 10 active sites enrolling patients for the pivotal ALPHA3 trial, in both the community and academic settings.
CollaborationsAllogene recently entered into a licensing agreement with Arbor Biotechnologies for the use of Arbor’s proprietary CRISPR gene-editing technology.
Financial PerformanceAllogene ended 2Q24 with ~$444.6M in cash and equivalents; this should support an operational runway extending into 2H26, spanning multiple potentially impactful data readouts.